Tackling COVID-19 with neutralizing monoclonal antibodies
Monoclonal antibodies (mAbs) have revolutionized the treatment of several human
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …
[HTML][HTML] Novel SARS-CoV-2 variants: the pandemics within the pandemic
Background Many new variants of the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) have been termed variants of concern/interest (VOC/I) because of the greater …
(SARS-CoV-2) have been termed variants of concern/interest (VOC/I) because of the greater …
Escape of SARS-CoV-2 501Y. V2 from neutralization by convalescent plasma
SARS-CoV-2 variants of concern (VOC) have arisen independently at multiple locations,
and may reduce the efficacy of current vaccines that target the spike glycoprotein of SARS …
and may reduce the efficacy of current vaccines that target the spike glycoprotein of SARS …
Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016
Monoclonal antibodies and antibody cocktails are a promising therapeutic and prophylaxis
for coronavirus disease 2019 (COVID-19). However, ongoing evolution of severe acute …
for coronavirus disease 2019 (COVID-19). However, ongoing evolution of severe acute …
Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials
The current study systematically reviewed, summarized and meta-analyzed the clinical
features of the vaccines in clinical trials to provide a better estimate of their efficacy, side …
features of the vaccines in clinical trials to provide a better estimate of their efficacy, side …
The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines
M Mohammadi, M Shayestehpour… - Brazilian Journal of …, 2021 - SciELO Brasil
Since the first described human infection with SARS-CoV-2 in December of 2019 many
subunit protein vaccines have been proposed for use in humans. Subunit vaccines use one …
subunit protein vaccines have been proposed for use in humans. Subunit vaccines use one …
Neutralising antibody escape of SARS‐CoV‐2 spike protein: risk assessment for antibody‐based Covid‐19 therapeutics and vaccines
The Spike protein is the target of both antibody‐based therapeutics (convalescent plasma,
polyclonal serum, monoclonal antibodies) and vaccines. Mutations in Spike could affect …
polyclonal serum, monoclonal antibodies) and vaccines. Mutations in Spike could affect …
[HTML][HTML] The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages
The independent emergence late in 2020 of the B. 1.1. 7, B. 1.351, and P. 1 lineages of
SARS-CoV-2 prompted renewed concerns about the evolutionary capacity of this virus to …
SARS-CoV-2 prompted renewed concerns about the evolutionary capacity of this virus to …
B. 1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies
H Zhou, BM Dcosta, MI Samanovic, MJ Mulligan… - MBio, 2021 - Am Soc Microbiol
ABSTRACT DNA sequence analysis recently identified the novel SARS-CoV-2 variant B.
1.526 that is spreading at an alarming rate in the New York City area. Two versions of the …
1.526 that is spreading at an alarming rate in the New York City area. Two versions of the …
Convalescent-phase sera and vaccine-elicited antibodies largely maintain neutralizing titer against global SARS-CoV-2 variant spikes
The increasing prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) variants with spike protein mutations raises concerns that antibodies elicited by natural …
2) variants with spike protein mutations raises concerns that antibodies elicited by natural …